Having trouble accessing articles? Reset your cache.

Alzheimer’s prevention replays the same amyloid failures as the treatment setting

Lilly’s solanezumab, Roche’s gantenerumab miss DIAN-TU endpoint in presymptomatic AD patients

The Phase II/III DIAN-TU trial of Lilly’s solanezumab and Roche’s gantenerumab was always a long shot, given the previous late-stage failures of both agents in Alzheimer’s trials. Perhaps more surprising is that both compounds remain in development.

On Monday, Eli Lilly and Co. (NYSE:LLY) and Roche (SIX:ROG; OTCQX:RHHBY) announced that the anti-amyloid therapies solanezumab and gantenerumab each missed the primary endpoint of slowing cognitive decline in the investigator-led study, which

Read the full 692 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE